Markets:

Overview

News

Currencies

International

Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.981 -0.299 (-9.11%)

Streaming Delayed Price Updated: 11:43 AM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

January 27, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

NRx Pharma's COVID-19 Vaccine Candidate Show Potential Against Omicron Variant ↗

January 27, 2022

NRx Pharmaceuticals (NASDAQ: NRXP) has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife vaccine can

Via Benzinga

Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 26, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

January 26, 2022

From Law Offices of Howard G. Smith

Via Business Wire

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19 ↗

January 26, 2022

NRx Pharmaceuticals (NASDAQ: NRXP) has

Via Benzinga

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data ↗

January 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 25, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

January 25, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 24, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

January 24, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders

January 23, 2022

From Robbins LLP

Via Business Wire

Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 21, 2022

Los Angeles - (NewMediaWire) - January 21, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc....

Via NewMediaWire

Topics Lawsuit

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

January 21, 2022

From Law Offices of Howard G. Smith

Via Business Wire

Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 20, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

January 20, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders

January 20, 2022

From Robbins LLP

Via Business Wire

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 20, 2022

From The Schall Law Firm

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

January 20, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

January 19, 2022

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

January 19, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors

January 19, 2022

From Law Offices of Howard G. Smith

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 19, 2022

From The Schall Law Firm

Via Business Wire

NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPW

January 18, 2022

From Rosen Law Firm

Via Business Wire

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments ↗

January 18, 2022

NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients to receive Zyesami (...

Via Benzinga

The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗

January 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...

Via Benzinga

NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights ↗

January 13, 2022

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing...

Via Benzinga

20 Stocks Moving in Monday's Pre-Market Session ↗

January 10, 2022

Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-...

Via Benzinga

DTST Stock Alert: The Pro Sports Deal That Has Data Storage Shares Soaring Today ↗

January 05, 2022

Data Storage (DTST) stock is soaring higher on Wednesday after announcing a massive deal with an unnamed sports team in the U.S.

Via InvestorPlace

WEJO Stock: 9 Things to Know About Wejo Group as Microsoft Deal Shines Light on the AV Player ↗

January 05, 2022

Wejo Group (WEJO) stock is rising higher on Wednesday after announcing a deal with Microsoft for a vehicle data platform.

Via InvestorPlace

NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today ↗

January 05, 2022

News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.

Via InvestorPlace

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

All News about NRX Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today